Related Experiment Video

Updated: Nov 27, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

Wentao Tian1,2, Chenghui Cao1,2, Long Shu1

  • 1Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China.

Oncotargets and Therapy
|December 2, 2020
PubMed

Insights

Anti-angiogenic therapy shows limited success alone in cancer treatment. Combining it with chemotherapy, radiotherapy, or immunotherapy offers promising efficacy by normalizing tumor blood vessels.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Tumor growth relies on angiogenesis, the formation of new blood vessels, for nutrient and oxygen supply.
  • Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) are common cancer treatments.
  • Monotherapy with anti-angiogenic agents is often ineffective due to tumor cell adaptation to hypoxia.

Purpose of the Study:

  • To review tumor angiogenesis characteristics.
  • To explore mechanisms of combining anti-angiogenic therapy with other treatments.
  • To discuss clinical applications and prospects for non-small cell lung cancer.

Main Methods:

  • Literature review on tumor angiogenesis.
  • Analysis of mechanisms underlying combination therapies.
  • Evaluation of clinical data for anti-angiogenic therapy combinations.

Main Results:

  • Anti-angiogenic therapy alone can induce hypoxia and promote tumor cell survival.
  • Combining anti-angiogenic therapy with chemotherapy, radiotherapy, immunotherapy, or anti-EGFR therapy shows enhanced efficacy.
  • Vessel normalization induced by anti-angiogenic agents is key to improved outcomes in combination strategies.

Conclusions:

  • Combination therapy holds significant promise for improving non-small cell lung cancer treatment outcomes.
  • Understanding tumor angiogenesis is crucial for developing effective anti-cancer strategies.
  • Further research into optimizing combination regimens is warranted.
Keywords:
angiogenesisanti-angiogenesis therapycombination therapyimmunotherapynon-small cell lung cancer

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.2K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
899
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
291
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K